Company / Interest Expense
BioXcel Therapeutics, Inc. Interest Expense History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$15.3M
FY2025
5-year range
$40.0K / $15.3M
FY2022-FY2025
Trend
+28.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Interest Expense has increased for 3 consecutive years, from $40,000 in FY2022 to $15M in FY2025.
Based on SEC 10-K filings.
$15M in FY2025 with a 3-year CAGR of +626.4%.
Increased from $8M to $15M over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +626.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- BioXcel Therapeutics, Inc.'s interest expense has grown for 3 consecutive years.
- 3-year CAGR of +626.4%, indicating consistent growth.
- In FY2025, interest expense increased 28.4% year-over-year.
Company context
Key Data Points
- Altman Z-Score -17.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $15.3M | +28.4% |
| FY2024 | $11.9M | +45.4% |
| FY2023 | $8.2M | +20432.5% |
| FY2022 | $40.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026